Investors Purchase Large Volume of Teladoc Health Call Options (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) saw some unusual options trading activity on Thursday. Stock traders acquired 15,699 call options on the stock. This represents an increase of approximately 132% compared to the typical volume of 6,766 call options.

Insider Activity at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the sale, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teladoc Health

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its stake in Teladoc Health by 33.3% in the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock valued at $70,000 after buying an additional 2,052 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Teladoc Health by 9.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 29,722 shares of the health services provider’s stock valued at $172,000 after purchasing an additional 2,578 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Teladoc Health by 20.8% in the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider’s stock valued at $143,000 after acquiring an additional 2,893 shares during the period. Allworth Financial LP purchased a new position in Teladoc Health in the 2nd quarter worth approximately $25,000. Finally, Twin Lakes Capital Management LLC acquired a new stake in shares of Teladoc Health during the second quarter valued at about $26,000. 76.82% of the stock is owned by institutional investors.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
• Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
• Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
• Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
• Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
• Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

Teladoc Health Price Performance

TDOC opened at $8.52 on Friday. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.91 and a beta of 2.14. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The company has a fifty day moving average price of $6.23 and a 200-day moving average price of $6.47.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative return on equity of 11.52% and a negative net margin of 6.27%. The firm had revenue of $605.10 million during the quarter, compared to the consensus estimate of $588.14 million. During the same quarter last year, the company posted ($0.28) EPS. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. On average, analysts expect that Teladoc Health will post -0.88 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on TDOC. Citigroup reduced their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a report on Monday, August 3rd. Bank of America raised their price target on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Stifel Nicolaus increased their price objective on Teladoc Health from $5.50 to $6.50 and gave the stock a “hold” rating in a report on Thursday. Finally, Canaccord Genuity Group cut their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and a consensus price target of $7.77.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.